Introduction Lower network segregation is associated with accelerated cognitive decline in
Alzheimer's disease (AD), yet it is unclear whether less segregated brain networks facilitate …

Alzheimer's disease (AD) phenotypes might result from differences in selective vulnerability.
Evidence from preclinical models suggests that tau pathology has cell-to-cell propagation …

In Alzheimer's diseases (AD), tau pathology is strongly associated with cognitive decline.
Preclinical evidence suggests that tau spreads across connected neurons in an activity …

Background The clinical features of Alzheimer's disease (AD) vary substantially depending
on whether the onset of cognitive deficits is early or late. The amount and distribution …

Alzheimer's disease (AD) is a brain network disorder where pathological proteins
accumulate through networks and drive cognitive decline. Yet, the role of network …

A key hallmark of Alzheimer's disease (AD) pathology is the intracellular accumulation of tau
protein in the form of neurofibrillary tangles across large-scale networks of the human brain …

Background Changes in grey matter covariance networks have been reported in preclinical
and clinical stages of Alzheimer's disease (AD) and have been associated with amyloid-β …

Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it
remains unclear how these proteins interact to promote disease. Here, by combining cross …

Objective We aimed to test whether region‐specific factors, including spatial expression
patterns of the tau‐encoding gene MAPT and regional levels of amyloid positron emission …

Understanding the role of Tau protein aggregation in the pathogenesis of Alzheimer's
disease is critical for the development of new Tau-based therapeutic strategies to slow or …